

# Mouse Anti-Avelumab monoclonal antibody, clone 23H0 (CABT-ZB181)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

| | |
|---|---|
| **Product Overview** | CABT-ZB181 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Avelumab. |
| **Specificity** | This product is specific for Avelumab. |
| **Target** | Avelumab |
| **Immunogen** | Avelumab |
| **Isotype** | IgG1, κ |
| **Source/Host** | Mouse |
| **Clone** | 23H0 |
| **Purification** | Protein A purified |
| **Conjugate** | Unconjugated |
| **Applications** | Suitable for PK bridging ELISA.<br>We recommend the following for sandwich ELISA (Capture - Detection): CABT-ZB180 - CABT-ZB181.<br>Each laboratory should determine an optimum working titer for use in its particular application.<br>Other applications have not been tested but use in such assays should not necessarily be excluded. |
| **Reconstitution** | Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| **Format** | Purified, Lyophilized. |

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221

| | |
|---|---|
| **Size** | 40 µg |
| **Buffer** | Lyophilized with PBS, pH 7.2, contains 0.02% sodium azide. |
| **Preservative** | 0.02% sodium azide |
| **Storage** | The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles. |
| **Ship** | Wet ice |

# BACKGROUND

| | |
|---|---|
| **Introduction** | Avelumab with trade name Bavencio, is an FDA-approved drug to treat Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma. Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by Avelumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition". |
| **Keywords** | Mouse monoclonal antibody to Avelumab/Bavencio; Avelumab; Bavencio |

# GENE INFORMATION

| | |
|---|---|
| **Synonyms** | Mouse monoclonal antibody to Avelumab/Bavencio; Avelumab; Bavencio |

45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-diagnostics.com
Tel: 1-631-624-4882 Fax: 1-631-938-8221